These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

748 related items for PubMed ID: 26535119

  • 1. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P.
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [Abstract] [Full Text] [Related]

  • 2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 3. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ, Jensen CB, Wennerström C, Burisch J, Petersen J.
    Scand J Gastroenterol; 2023 Jul 14; 58(7):726-736. PubMed ID: 36802972
    [Abstract] [Full Text] [Related]

  • 4. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.
    Rawla P, Sunkara T, Raj JP.
    J Inflamm Res; 2018 Jul 14; 11():215-226. PubMed ID: 29844695
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
    Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, Kuenzig E, Tomlinson G, Siegel CA, Melmed GY, Kaplan GG.
    Gastroenterology; 2015 Feb 14; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
    [Abstract] [Full Text] [Related]

  • 6. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review.
    Cao WT, Huang R, Jiang KF, Qiao XH, Wang JJ, Fan YH, Xu Y.
    World J Gastroenterol; 2021 Mar 07; 27(9):886-907. PubMed ID: 33727776
    [Abstract] [Full Text] [Related]

  • 7.
    Ringerike T, Elvsaas IKØ, Coll P, Lundin KEA, Movik E, Gjertsen MK.
    ; 2008 12 07. PubMed ID: 29320135
    [Abstract] [Full Text] [Related]

  • 8. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP, Chaparro M.
    J Crohns Colitis; 2020 Jun 19; 14(5):694-709. PubMed ID: 31777929
    [Abstract] [Full Text] [Related]

  • 9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.
    Dig Liver Dis; 2005 Jun 19; 37(6):407-17. PubMed ID: 15893279
    [Abstract] [Full Text] [Related]

  • 10.
    Chao YS, Loshak H.
    ; 2019 04 17. PubMed ID: 31693324
    [Abstract] [Full Text] [Related]

  • 11. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN.
    Aliment Pharmacol Ther; 2017 May 17; 45(10):1291-1302. PubMed ID: 28326566
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukáš M, Reinisch W, Roblin X, Jang M, Byun HG, Kim DH, Lee SJ, Atreya R.
    BMC Gastroenterol; 2022 Jun 08; 22(1):291. PubMed ID: 35676620
    [Abstract] [Full Text] [Related]

  • 13. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.
    J Am Acad Dermatol; 2018 Feb 08; 78(2):383-394. PubMed ID: 29332708
    [Abstract] [Full Text] [Related]

  • 14. Biologic therapies in inflammatory bowel disease.
    Cohen LB, Nanau RM, Delzor F, Neuman MG.
    Transl Res; 2014 Jun 08; 163(6):533-56. PubMed ID: 24467968
    [Abstract] [Full Text] [Related]

  • 15. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, DenmarkSpecial Reporting on:• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With VedolizumabPLUS Meeting Abstract Summaries With Expert Commentary by: Edward V. Loftus Jr, MDProfessor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota.
    Gastroenterol Hepatol (N Y); 2019 May 08; 15(5 Suppl 2):1-24. PubMed ID: 31632213
    [No Abstract] [Full Text] [Related]

  • 16. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U.
    Gastroenterology; 2018 Sep 08; 155(3):696-704. PubMed ID: 29857090
    [Abstract] [Full Text] [Related]

  • 17. Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease.
    Wilson M, Lucas A, Cameron A, Luo M.
    Am Health Drug Benefits; 2018 Jul 08; 11(5):253-262. PubMed ID: 30464793
    [Abstract] [Full Text] [Related]

  • 18. Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic review.
    Byrne LW, McKay D.
    Surgeon; 2021 Oct 08; 19(5):e153-e167. PubMed ID: 34581275
    [Abstract] [Full Text] [Related]

  • 19. Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.
    Ehrenberg R, Griffith J, Theigs C, McDonald B.
    J Manag Care Spec Pharm; 2020 Jun 08; 26(6):758-765. PubMed ID: 32191593
    [Abstract] [Full Text] [Related]

  • 20. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.
    J Crohns Colitis; 2014 Feb 08; 8(2):120-8. PubMed ID: 23932783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.